var quiz = [
  {
    q: `Lower urinary tract symptoms (LUTSs) may arise as a consequence of:`,
    q2: ``,
    q3: [],
    option: [
      `benign prostatic enlargement.`,
      `bladder outlet obstruction.`,
      `neurologic disease.`,
      ` detrusor underactivity.`,
      ` all of the above.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: LUTSs are considered a clinical manifestation with a multifactorial pathophysiology arising from different conditions, including benign prostatic enlargement, bladder outlet obstruction, neurologic disease, and bladder dysfunction.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
  },

  {
    q: `Medications that may exacerbate LUTSs include:`,
    q2: ``,
    q3: [],
    option: [
      `loop diuretics.`,
      `α adrenergic antagonists.`,
      `β-3 adrenergic agonists.`,
      `muscarinic receptors agonists. `,
      ` phytotherapy`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: Loop diuretics may increase urinary output, exacerbating symptoms in patients with bladder outlet obstruction.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
  },

  {
    q: `Digital rectal examination at the time of the assessment of patients with LUTSs:`,
    q2: ``,
    q3: [],
    option: [
      `should always be performed with the only aim to rule out prostate cancer.`,
      `allows estimation of prostate volume, which is useful for planning further management.`,
      `does not provide reliable information, and therefore should not be performed.`,
      `may be used to obtain prostatic secretion. `,
      `has the main goal of estimating the rectal tone. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: Digital rectal examination should always be performed at the first assessment of patients with LUTS. It can provide an estimate of prostate volume and at the same time rule out locally advanced prostate cancer.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
  },

  {
    q: `Frequency-volume charts:`,
    q2: ``,
    q3: [],
    option: [
      `should always be used when patients with LUTSs are being assessed.`,
      `should cover at least a 72-hour period.`,
      `are particularly useful to assess obstructive symptoms.`,
      `allows estimation of the average postvoid residual volume. `,
      ` should be requested only when a diagnosis of detrusor overactivity has been established.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: A 3-day period is considered a reasonable compromise to increase the accuracy of frequency-volume charts without decreasing patient adherence.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `It is advisable in a man with LUTSs/benign prostatic hyperplasia and a slightly elevated creatinine level to perform:`,
    q2: ``,
    q3: [],
    option: [
      `transurethral resection of the prostate.`,
      `an intravenous pyelogram.`,
      `renal ultrasound imaging.`,
      `a urodynamic study. `,
      `flexible cystoscopy. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: International clinical guidelines suggest upper urinary tract imaging in the case of elevated serum creatinine level.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
  },

  {
    q: `Which test should always be considered in a man with prevalent storage symptoms and a history of smoking?`,
    q2: ``,
    q3: [],
    option: [
      `Urinalysis`,
      `Serum prostate-specific antigen (PSA) test.`,
      `Urine cytology.`,
      `Frequency-volume charts. `,
      `Noninvasive urodynamic tests. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: This test should be considered in patients presenting with storage symptoms and a history of smoking to rule out urothelial neoplasms.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Serum PSA testing should be requested in which of the following clinical scenarios?`,
    q2: ``,
    q3: [],
    option: [
      `A patient older than 75 years with a family history of prostate cancer.`,
      `A 55-year-old patient with negative digital rectal examination findings and no previous PSA measurements.`,
      `Serum PSA should be performed every case to rule out prostate cancer.`,
      `A patient with severe symptoms regardless of age. `,
      `A patient with a recent episode of macrohematuria. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: Among patients with LUTSs, PSA testing should be suggested if a diagnosis of prostate cancer would change the clinical management.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `What is the gold standard for the assessment of bladder outlet obstruction?`,
    q2: ``,
    q3: [],
    option: [
      `Invasive urodynamic tests.`,
      `Uroflowmetry`,
      `Transrectal prostate ultrasound imaging.`,
      ` Flexible urethrocystoscopy.`,
      ` Cystourethrogram`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: The diagnosis of bladder outlet obstruction relies on urodynamic tests.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `What is the suggested first treatment approach for a 50-year-old patient with an International Prostate Symptom Score (IPSS) score of 7 without risk factors for disease progression?`,
    q2: ``,
    q3: [],
    option: [
      `Phytotherapy`,
      `α Adrenergic blockers.`,
      `Watchful waiting.`,
      `No treatment. `,
      `β3 Adrenergic agonists. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: Patients with mild symptoms without factors suggesting a high risk of disease progression (e.g., large postvoid volume, large prostate volume) should be counseled for conservative management.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Which of the following strategies should be part of watchful waiting management?`,
    q2: ``,
    q3: [],
    option: [
      `Regular patient monitoring.`,
      `Education and reassurance.`,
      `Fluid management.`,
      ` Concurrent medication adjustment.`,
      `All of the above. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: Watchful waiting is mainly based on lifestyle modifications, education, and reassurance and monitoring.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Which of the following is an indication for surgical treatment in patients with LUTSs?`,
    q2: ``,
    q3: [],
    option: [
      `Severe symptoms.`,
      `Postvoid residual volume urine of 300 mL or more.`,
      `Recurrent episodes of acute urinary retention.`,
      `Elevated PSA level. `,
      ` Lack of response to an α-blocker.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: Surgical treatment of LUTSs is indicated for patients with recurrent acute urinary retention because they may not benefit from medical treatment.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Detrusor overactivity:`,
    q2: ``,
    q3: [],
    option: [
      `is always an indicator of overactive bladder syndrome.`,
      `is rarely observed in patients with benign prostatic enlargement.`,
      `may be observed in up to 83% of men with severe bladder outlet obstruction.`,
      `should always be reduced by LUTS treatment. `,
      `None of the above sentences are true. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: Detrusor overactivity is extremely common in the case of bladder outlet obstruction; however, LUTS treatment may not reduce detrusor overactivity.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Which of the following receptors is not relevant for LUTS treatment?`,
    q2: ``,
    q3: [],
    option: [
      `α-1<sub>a</sub>.`,
      `α-1<sub>b</sub>`,
      `α-1<sub>d</sub>.`,
      ` β-3.`,
      ` β-1.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: Among adrenergic receptors, the β-1 subfamily is poorly represented in the lower urinary tract and is not targeted by any of the currently available treatments for LUTSs. `,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Which of the following is considered a uroselective α adrenergic blocker?`,
    q2: ``,
    q3: [],
    option: [
      `Terazosin`,
      `Sildenafil`,
      `Tamsulosin`,
      `Doxazosin `,
      `None of them. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: Uroselective agents have high affinity for the α-1<sub>a</sub> and α-1<sub>d</sub> receptors; as such, they have greater selectivity for prostatic and urethral tissue.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `In the first placebo-controlled phase III trial, terazosin showed a symptom-reduction rate of approximately:`,
    q2: ``,
    q3: [],
    option: [`22%.`, `13%.`, `85%.`, `40%. `, ` 8%.`],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: The first phase III multicenter, placebo-controlled trial showed a 22.4% reduction in symptom score from the baseline for patients treated with terazosin.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `One of the most commonly reported side effects with terazosin therapy is:`,
    q2: ``,
    q3: [],
    option: [
      `retrograde ejaculation.`,
      `anejaculation`,
      `headache`,
      ` dyspepsia`,
      `dizziness `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: As a consequence of the vascular side effects associated with the inhibition of α-1<sub>b</sub> receptors, dizziness is frequently reported after treatment with terazosin and doxazosin.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Pooled data analysis of randomized trials showed that the relative risk of postural hypotension with doxazosin treatment as compared with placebo is:`,
    q2: ``,
    q3: [],
    option: [
      `approximately 2.7.`,
      `approximately 5.6.`,
      `approximately 7.8.`,
      `approximately 1.1. `,
      ` not different.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: A meta-analysis of 10 placebo-controlled trials showed that the relative risk of postural hypotension associated with doxazosin treatment was 2.72 (95% confidence interval 1.21–6.15).`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `The Medical Therapy of Prostatic Symptoms (MTOPS) trial showed that treatment with doxazosin was associated with:`,
    q2: ``,
    q3: [],
    option: [
      `reduced risk of clinical progression as compared with placebo.`,
      `increased risk of acute urinary retention as compared with placebo.`,
      `no change in the risk of clinical progression as compared with placebo.`,
      ` reduced risk of surgical treatment as compared with finasteride.`,
      ` none of the above.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: In the MTOPS trial, doxazosin therapy resulted in a significant decrease in the risk of clinical progression as compared with placebo, although it was inferior to both finasteride monotherapy and combination therapy.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Which of the following drugs needs dose titration at first prescription:`,
    q2: ``,
    q3: [],
    option: [
      `Finasteride`,
      `Alfuzosin`,
      `Terazosin`,
      `Doxazosin gastrointestinal therapeutic system. `,
      ` Tamsulosin`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: Given the high risk of first-dose hypotension, nonuroselective α-blockers need dose titration over the first few weeks of treatment.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `An effect of tamsulosin on patient symptoms should be expected after approximately:`,
    q2: ``,
    q3: [],
    option: [
      `1 month of treatment.`,
      `6 months of treatment.`,
      `1 week of treatment.`,
      `3 months of treatment. `,
      ` 1 day of treatment.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [3],
    ansText: `Rationale: Randomized trials have shown that tamsulosin leads to symptom relief after 1 week of treatment and to changes in urinary flow parameters after only a few hours.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
  },

  {
    q: `What is the magnitude of the change of the bladder outlet obstruction index (BOOI) after treatment with silodosin?`,
    q2: ``,
    q3: [],
    option: [
      `−30.4.`,
      `−5.4.`,
      `−11.1. `,
      ` −2.1`,
      `Treatment with α adrenergic blockers is never associated with an improvement of urodynamic parameters.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: In a recent study pooling data from trials assessing urodynamic changes associated with α-blocker treatment, silodosin showed the greatest BOOI reduction as compared with the other compounds.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Naftopidil has demonstrated high affinity for which of the following receptors?`,
    q2: ``,
    q3: [],
    option: [
      `α-1<sub>b</sub>.`,
      `α-1<sub>a</sub>.`,
      `α-1<sub>a</sub> and α-1<sub>b</sub>.`,
      `β3. `,
      ` α-1<sub>d</sub>.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: Naftopidil is the only developed compound with a distinct selectivity for the α-1<sub>d</sub> receptor subtype.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Randomized active-controlled trials comparing the effect of different α adrenergic blockers demonstrated that:`,
    q2: ``,
    q3: [],
    option: [
      `tamsulosin at a dose of 0.4 mg is as effective as silodosin at a dose of 8 mg in terms of symptom relief.`,
      `alfuzosin at a daily dose of 10 mg has lower overall efficacy as compared with tamsulosin at a dose of 0.4 mg.`,
      `tamsulosin at a dose of 0.4 mg showed the greatest BOOI reduction among all available α adrenergic blockers.`,
      `uroselective α adrenergic blockers are generally more effective than doxazosin and terazosin. `,
      ` there is no clinically relevant difference in the efficacy and tolerability profile among α adrenergic blockers.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: Data from two meta-analyses of randomized controlled trials comparing silodosin with tamsulosin showed no difference in terms of efficacy.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Physicians should warn patients regarding the risk of first-dose hypotension when prescribing:`,
    q2: ``,
    q3: [],
    option: [
      `silodosin`,
      `tamsulosin`,
      `terazosin`,
      ` alfuzosin`,
      ` all of the above.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: Despite the lower risk of vascular side effects associated with uroselective α-blockers, patients should be always warned regarding the risk of first-dose hypotension.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `What is the likely mechanism for dizziness after α-1 adrenergic blocker therapy?`,
    q2: ``,
    q3: [],
    option: [
      `Reduced cardiac output.`,
      `Central nervous system.`,
      `Carotid baroreceptor.`,
      `Both a and c. `,
      ` None of the above.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: The α-1–mediated dizziness and asthenia are likely due to effects at the level of the central nervous system.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Before they undergo cataract surgery, patients should be advised to:`,
    q2: ``,
    q3: [],
    option: [
      `discontinue treatment with α-blockers to reduce the risk of intraoperative floppy iris syndrome (IFIS).`,
      `report the use of α-blockers to the ophthalmologist.`,
      `discontinue treatment with tamsulosin and switch to a nonuroselective α-blocker.`,
      `reduce the dosage of the α-blocker at least 1 month before surgery. `,
      ` do none of the above.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: IFIS cannot be prevented, but the ophthalmologist should be notified regarding the use of α-blockers so as to properly manage complications. `,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Which of the following effects should be expected after 1 month of treatment with finasteride?`,
    q2: ``,
    q3: [],
    option: [
      `Significant decrease in serum dihydrotestosterone (DHT) level.`,
      `Significant decrease in prostate volume.`,
      `ignificant increase in the peak urinary flow.`,
      ` 70% decrease in serum PSA level.`,
      `None of the above `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: As a type 1 5-ARI, finasteride does not lower the serum level of DHT. Moreover, 1 month of treatment is not enough to observe a significant change in prostate volume and urinary flow parameters. Conversely, PSA level may change after 1 month of treatment.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `What is the expected decrease in prostate volume with 5-α reductase inhibitors (5-ARIs)?`,
    q2: ``,
    q3: [],
    option: [`15% to 30%.`, `More than 50%.`, `10%.`, `80%. `, ` 5%.`],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [3],
    ansText: `Rationale: Randomized trials assessing treatment with dutasteride and finasteride have shown a prostate volume reduction ranging from 15% to 30% after 6 to 24 months of treatment.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Regarding the safety profile of 5-ARIs:`,
    q2: ``,
    q3: [],
    option: [
      `5-ARIs may increase the risk of diabetes mellitus.`,
      `patients treated with 5-ARIs showed higher risk of cardiovascular events.`,
      `5-ARIs may increase the overall risk of prostate cancer.`,
      `patients should be warned regarding a higher risk of depressive symptoms associated with 5-ARI treatment. `,
      `none of the above are true. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: Large prospective trials have shown a higher prevalence of depressive symptoms among patients treated with 5-ARIs.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Tolterodine should not be prescribed to a patient with:`,
    q2: ``,
    q3: [],
    option: [
      `a total IPSS score suggestive of severe symptoms.`,
      `postvoid residual volume greater than 200 mL.`,
      `evidence of detrusor overactivity.`,
      `low cystometric capacity. `,
      `prostate volume greater than 50 mL. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: All trials investigating antimuscarinic drugs included only patients with a postvoid residual volume lower than 200 mL.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Who is the best candidate for treatment with mirabegron?`,
    q2: ``,
    q3: [],
    option: [
      `A 75-year-old patient with prevalent storage symptoms.`,
      `A 65-year-old patient with moderate LUTSs and a postvoid residual volume of 250 mL.`,
      `A 70-year-old patient with moderate LUTSs and a previous episode of acute urinary retention.`,
      `A 45-year-old patient with mild LUTSs and erectile dysfunction. `,
      ` None of the above.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: Given its more favorable tolerability profile as compared with antimuscarinic drugs, mirabegron therapy could be preferred in old men with prevalent storage symptoms.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Which of the following is considered a possible biologic effect of phosphodiesterase type 5 inhibitors (PDE5is) on the lower urinary tract?`,
    q2: ``,
    q3: [],
    option: [
      `Relaxation of smooth muscle at the level of the prostate and bladder neck.`,
      `Decreased blood flow at the level of the bladder and prostate resulting in decreased local inflammation.`,
      `Increased activity of afferent nerves in the bladder wall.`,
      `Inhibition of the 5α-reductase type 2 isoenzyme at the level of the prostate. `,
      `All of the above. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: This effect is associated with the increase in nitric oxide signaling from nerve fibers close to the muscle fibers.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `What is the effect of PDE5i monotherapy in patients with LUTSs?`,
    q2: ``,
    q3: [],
    option: [
      `There is no evidence of a significant reduction in the IPSS score with PDE5i monotherapy alone.`,
      `PDE5i monotherapy resulted in a significant increase in the peak urinary flow after 1 month of treatment.`,
      `PDE5i monotherapy has been shown to significantly decrease the IPSS score as compared with placebo.`,
      ` Tadalafil is the only PDE5i that has resulted in relief of symptoms in randomized trials.`,
      ` PDE5i monotherapy can decrease the risk of acute urinary retention in the long term.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: Several randomized trials demonstrated significant relief of symptoms associated with PDE5i monotherapy. Conversely, there is no evidence of improved urinary flow parameters with PDE5is alone.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `Pooled data analysis has shown that the mean difference in the posttreatment IPSS between PDE5is and placebo is:`,
    q2: ``,
    q3: [],
    option: [
      `approximately 2 to 4 points.`,
      `approximately 6 to 8 points.`,
      `approximately 1 to 2 points.`,
      ` not significant.`,
      `none of the above. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: Meta-analyses of placebo-controlled trials have shown a mean difference in the posttreatment IPSS score, between PDE5is and placebo, ranging from 2 to 4 points.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `The MTOPS trial showed that:`,
    q2: ``,
    q3: [],
    option: [
      `the combination of doxazosin and finasteride is superior to placebo in reducing the risk of clinical progression.`,
      `doxazosin is not superior to placebo in reducing the risk of clinical progression.`,
      `finasteride alone does not reduce the risk of subsequent invasive therapy as compared with placebo.`,
      ` combination therapy is not superior to doxazosin monotherapy in terms of symptom relief.`,
      `doxazosin is superior to placebo in reducing the risk of subsequent invasive therapy. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: The MTOPS trial demonstrated that combination therapy of an α-blocker and a 5-ARI can significantly reduce the risk of disease progression at long-term follow-up. This effect was greater than with both placebo and monotherapy. `,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `The Combination of Avodart and Tamsulosin (CombAT) study showed that:`,
    q2: ``,
    q3: [],
    option: [
      `tamsulosin monotherapy significantly reduces the risk of acute urinary retention.`,
      `dutasteride alone reduces the risk of surgical treatment as compared with tamsulosin.`,
      `combination therapy is not superior than dutasteride monotherapy in reducing the risk of disease progression.`,
      ` tamsulosin is superior to dutasteride in reducing the IPSS score at long-term assessment.`,
      ` None of the above.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: The CombAT study showed a greater reduction in the risk of surgical treatment for patients treated with dutasteride as compared with tamsulosin.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `According to international clinical guidelines, a patient with a large prostate volume and predominantly bothersome voiding symptoms should be counseled for:`,
    q2: ``,
    q3: [],
    option: [
      `surgical treatment.`,
      `α-blocker plus 5-ARI therapy`,
      `α-blocker monotherapy.`,
      ` 5-ARI monotherapy.`,
      `α-blocker plus antimuscarinic drug therapy. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: Treatment algorithms suggest a combination of an α-blocker and a 5-ARI to treat patients with large gland volumes and bothersome voiding symptoms.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `The definitive mechanism of action for <i>Serenoa repens</i> is:`,
    q2: ``,
    q3: [],
    option: [
      `inhibition of 5α-reductase.`,
      `inhibition of cyclooxygenase.`,
      `inhibition of lipoxygenase.`,
      `prostate smooth muscle relaxation. `,
      `inconclusive `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: Although experimental data have suggested numerous possible mechanisms of actions for the phytotherapeutic agents, it is uncertain which, if any, of these proposed mechanisms is responsible for the clinical responses.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `The results of placebo-controlled trials assessing treatment with <i>S. repens</i> showed:`,
    q2: ``,
    q3: [],
    option: [
      `a significant reduction of symptom scores.`,
      `a reduction of the IPSS score only at triple the usual dose.`,
      `no difference in the urinary flow parameters but significant relief symptoms.`,
      `no difference in both symptoms and urinary flow parameters as compared with placebo. `,
      `None of the above. `,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [3],
    ansText: `Rationale: Although meta-analysis of randomized trials of <b><i>S. repens</i></b> did not show significant relief of LUTSs, it has been recognized that those results could be affected by the heterogeneity of the extracts used in the different trials and may not be applicable to all marketed products.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },

  {
    q: `In a patient with a first episode of acute urinary retention, what is the probability of a successful trial without catheter?`,
    q2: ``,
    q3: [],
    option: [
      `Approximately 60%.`,
      `Less than 50%.`,
      `Approximately 10%.`,
      `Very low without concomitant α-blocker therapy. `,
      ` More than 80%.`,
    ],
    optionFeedback: [``, ``, ``, ``, ``],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: Prospective studies have shown that a successful trial without catheter after a first episode of acute urinary retention could be achieved in 60% of cases.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
];
